Prospective, Observational Study to Identify Biomarkers in Parkinsonian Syndromes

What this Trial Is About

Researchers are conducting a prospective observational study to identify biomarkers in parkinsonian syndromes. The study focuses on patients in the early stages of these diseases, aiming to follow them until their clinical diagnosis is confirmed or for at least five years. This research collects imaging, wet biomarkers, and clinical data systematically to better understand these conditions. Participants include those with parkinsonian syndromes and healthy individuals without neurological diseases. The study collects various imaging outcomes such as nuclear medicine investigations, PET scans, DaTScan, and MRI at enrolment. Blood samples for DNA and biomarkers are taken at enrolment and after two years. Clinical scales for Parkinson's disease, progressive supranuclear palsy, multiple system atrophy, apathy, autonomic dysfunction, cognition, and frontal dysfunction are assessed every six months for up to five years. During the study, participants undergo regular evaluations including clinical scales, disease staging, and imaging tests. Blood samples are analyzed at specific intervals. The primary outcomes include demographics, family history, disease duration, symptom onset, and progression measured through clinical scales and imaging. This observational study lasts at least five years, with ongoing monitoring and data collection to track disease evolution and biomarker changes.

Biomarkers in Parkinsonian Syndromes